Chronic Kidney Disease

NCT01532349
Study Type: Interventional
Study Design: Allocation: Randomized
End Point Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title: Cholecalciferol as a Modifier of Serum Hepcidin in Children with Chronic Kidney Disease

Ages Eligible for Study: 1 to 21 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Sponsors and Collaborators:
Johns Hopkins University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Contact: Meredith Atkinson, MD 410-955-2467 matkins3@jhmi.edu
Contact: Sara Boynton 443-287-9051 sboynto3@jhmi.edu
NCT01581073
Study Type: Interventional
Study Design: Allocation: Randomized
End Point Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title: Prevention of End Stage Kidney Disease by Darbepoetin Alfa In CKD Patients with Non-diabetic Kidney Disease

Ages Eligible for Study: 20 to 85 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Sponsors and Collaborators
Translational Research Informatics Center, Kobe, Hyogo, Japan
Showa University School of Medicine

Contact: Shoichi Maruyama, MD, PhD-+81-52-744-2192, marus@med.nagoya-u.ac.jp

About Tori Socha